The purpose of the NASH Council is to shine a spotlight and coalesce an expanded set of stakeholders, in addition to hepatology, around the urgency of developing mechanisms for quantifying and addressing the silent epidemic of fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the U.S. and abroad. The NASH Council convenes twice per calendar year and may create workgroups to advance and develop specific concepts.
Membership is open to organizations worldwide with a demonstrated expertise in clinical medicine, research, public health, endocrinology/diabetes, cardiovascular health, obesity reduction, or wellness. Individuals able to demonstrate significant contributions to the areas of public health, endocrinology, cardiovascular health, obesity reduction or wellness may be eligible for membership.
NASH EL-PFDD Report
On November 4th 2021, Global Liver Institute led an Externally Led Patient-Focused Drug Development Meeting on NASH. This GLI led EL-PFDD meeting on NASH provided regulators, and drug developers the invaluable opportunity to hear from patients and caregivers directly about the challenges and burdens of this life-threatening condition.
U.S. NASH Action Plan [PDF]
GLI and the GLI NASH Council released the U.S. NASH Action Plan to comprehensively address NASH and its impact on patients and families, public health, and the economy. The plan includes a set of actionable recommendations for the full spectrum of groups involved in NASH prevention and treatment, including: patients and caregivers, clinicians, patient advocacy organizations, medical societies, industry, policymakers, regulators, health systems, and health insurance payers.
The Language of NASH: A Narrative Guide to Communication on NASH [PDF]
To increase awareness of fatty liver disease, we all need to speak the same language. This framework for communication about NAFLD and NASH will help physicians, patients, caregivers, families, and advocates use the same wording to send a clear message: it’s time to increase awareness, diagnosis and treatment options for NASH.
NASH Core Curriculum: A Comprehensive Online Resource Center
GLI, in collaboration with Clinical Care Options, has launched an online resource center to improve clinician understanding of foundational concepts in NASH diagnosis, management, and emerging pharmacologic treatment strategies. The resources will be added throughout the first half of 2021 and are being developed primarily for clinicians, including advanced practice clinicians, in hepatology, gastroenterology, endocrinology, and primary care. The full curriculum will include CME/CE-certified video modules, ClinicalThought™ expert commentaries, and downloadable presentations and resources.
GLI's NASH Collaborations
2021 NASH Diagnostics Forum™
GLI, Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore), and Integritas Communications (Integritas) have received an educational grant from Pfizer, Inc., to execute the 2021 NASH Diagnostics Forum™. The initiative, titled “A Critical Appraisal of Noninvasive Technologies in NASH: Informing the Future of NASH Diagnosis and Assessment,” will convene a multidisciplinary panel of experts to conduct a comprehensive analysis of available data on noninvasive biomarkers and tools for diagnosis, prognosis, and monitoring of NASH. The grant will also support dissemination of the Forum’s findings to the broader medical community via multiple media.
TARGET-NASH Observational Study
TARGET PharmaSolutions is a data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting. TARGET PharmaSolutions has announced it’s long-term strategic alliance for TARGET-NASH which originally launched August 2016. TARGET-NASH is a longitudinal observational study that evaluates adults and pediatric patients with NAFLD or NASH. The academic steering committee is chaired by Dr. Arun Sanyal, Dr. Ken Cusi, and Dr. Brent Tetri.
The NASH Education Program - A GENFIT Initiative
This program raises awareness around NASH and NAFLD by providing information and background on the many aspects of these conditions including disease state, prevalence, risk factors, diagnosis, and treatment.
NASH Summit
Join 150+ drug developers from 120+ organizations at this focused discussion and networking forum and gain actionable insights to accelerate the development of your NASH therapeutic pipeline.
The Liver Forum
The Liver Forum is an initiative of the Forum for Collaborative Research, part of the University of California, Berkeley School of Public Health. The Liver Forum was launched in 2014 in response to The Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease (NAFLD) meeting sponsored in 2013 by the U.S. Food and Drug Administration (FDA) and the American Association for the Study of Liver Disease (AASLD).
The Liver Forum aims to advance the regulatory sciences for the treatment of nonalcoholic steatohepatitis and liver fibrosis by providing an independent and neutral venue for ongoing multi-stakeholder dialogue to identify and address gaps in the field. Neutrality and objectivity is ensured through representation and active engagement of scientific experts from all stakeholder groups, including academia, industry, patient community and regulatory agencies.
GLI President and CEO Donna R. Cryer, JD is included in this expert group of stakeholders on the steering committee as a community representative.
The Liver Meeting
GLI brought the patient perspective to the digital forefront during The Liver Meeting Digital Experience (TLMdX) held by the American Association for the Study of Liver Diseases (AASLD) November 13-16, 2020. As part of their new strategic plan, AASLD has committed to actively engage with patients, and GLI staff highlighted the important role GLI has to play in implementing this strategy, in addition to sharing GLI’s advocacy work and goals. Read more about GLI’s involvement at the 2020 meeting.
GLI NASH Resources
Visit our NASH Resources page to view the latest NASH Resources from GLI.
NASH News
Archive
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- April 2017
- March 2017
- January 2017
- December 2016
- November 2016
- October 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- May 2015
- February 2015
- December 2014
- October 2014
- September 2014
- July 2014
NASH Council Members
To apply for membership, please fill out a Membership Application Form.
Allergan
American Association for the Study of Liver Diseases
American Association of Clinical Endocrinologists
American Association of Nurse Practitioners
American Cancer Society
American College of Physicians
American College of Physicians Assistants
American College of Sports Medicine
American Gastroenterological Association
American Heart Association
American Nursing Association
American Society for Gastrointestinal Endoscopy
Amsety
Apollo Endosurgery, Inc.
Association of American Medical Colleges
BlackDoctor.org
Boehringer Ingelheim
Bristol-Myers Squibb
Canadian Liver Foundation
Cancer and Chronic Disease Prevention: DC Department of Health
Cardiometabolic Health Congress
Celgene
Center for Medical Technology Policy
Clinical Care Options
Council for a Strong America
diaTribe
Duke University School of Medicine
Endocrine Society
European Liver Patients Association
Fatty Liver Alliance
Fatty Liver Foundation
Food & Drug Administration
Gartman PR
Genfit
George Washington University - Milken Institute School of Public Health
Gilead Sciences, Inc.
Integritas Communications
Intercept Pharmaceuticals
Joslin Diabetes Center
Karolinska Institute/University Hospital
Liver Patients International
Massachusetts General Hospital/Harvard Medical School: Fatty Liver Disease Clinic
McGuire VA Medical Center
Medical University of South Carolina
Merck
Metabolys Inc.
MHP Salud (formerly Migrant Health)
NASH kNOWledge
NASHNet
National Alliance for Hispanic Health
National Center for Weight and Wellness/Obesity Society
National Hispanic Medical Association
National Lipid Association
National Medical Association
Nestle Health Science
North American Society For Pediatric Gastroenterology, Hepatology & Nutrition
Northwestern University
Novartis
Novo Nordisk, Inc.
Obesity Action Campaign
Perspectum Diagnostics
Pfizer Inc.
Physicians Committee for Responsible Medicine
Preventive Cardiovascular Nurses Association
Regeneron Pharmaceuticals
Rush University
Rutgers University
STOP Obesity Alliance
Tampa General Medical Group/ USF Tampa
Target-NASH PharmaSolutions
Tawazun Health
The Liver Forum
University of California San Francisco Medical Center
University of Michigan NAFLD Clinic
Virginia Commonwealth University School of Medicine